Results 251 to 260 of about 482,699 (357)

Monitoring of Antigen-Specific Cytolytic T Lymphocytes in Cancer Patients Receiving Immunotherapy [PDF]

, 2000
Theresa L. Whiteside
openalex   +1 more source

What's in a name? Memory NK cells for cancer immunotherapy. [PDF]

J Immunother Cancer
Judge SJ, Purl MC, Murphy WJ, Canter RJ.
europepmc   +1 more source

Targeting KMT5C Suppresses Lung Cancer Progression and Enhances the Efficacy of Immunotherapy

Advanced Science, EarlyView.
This study reveals that KMT5C activates DNA damage repair to inhibit STING‐IRF3 pathway, downstream type I IFN signaling and CCL5 secretion, leading to the downregulation of CD8+ T cell infiltration and function in NSCLC, ultimately facilitating tumor progression.
Yunfeng Yuan, Qianyu Li, Guoquan Yan, Yifei Qian, Wenyun Guo, Songling Li, Fan Wang, Wanjing Shang, Zijun Zhu, Di Ge, Yanan Wang, Yanfeng Liu   +11 more
wiley   +1 more source

Editorial: Vector-based gene delivery in cancer immunotherapy. [PDF]

Front Immunol
Cheng N, Yang X, Chen D, Xu C.
europepmc   +1 more source

GRP78 Nanobody‐Directed Immunotoxin Activates Innate Immunity Through STING Pathway to Synergize Tumor Immunotherapy

Advanced Science, EarlyView.
A GRP78 nanobody‐directed immunotoxin suppresses cancer progression and metastasis by enhancing antitumor immunity via STING pathway activation, offering a pan‐cancer‐targeted approach and immunotherapy combination strategy. Abstract The lack of targetable antigens poses a significant challenge in developing effective cancer‐targeted therapies.
Huifang Wang, Runhua Zhou, Chengchao Xu, Lingyun Dai, Rui Hou, Liuhai Zheng, Chunjin Fu, Guangwei Shi, Jingwei Wang, Yang Li, Jinpeng Cen, Xiaolong Xu, Le Yu, Yilei Li, Jigang Wang, Qingfeng Du, Zhijie Li   +16 more
wiley   +1 more source

Immunotherapy of metastatic renal cell cancer

, 1996
S.H. Goey, Jaap Verweij, G. Stoter
openalex   +1 more source

Cancer Vaccines and Immunotherapy [PDF]

, 2000
Peter L. Stern, Peter C. L. Beverley, Miles W. Carroll   +2 more
openalex   +1 more source

Harnessing the power of ionising radiation to enhance cancer immunotherapy. [PDF]

Clin Transl Med
Pang K, Zhang Z.
europepmc   +1 more source

PCSK9 Promotes the Malignancy of Triple‐negative Breast Cancer Cells by Reducing Cholesterol Levels at the Plasma Membrane to Activate EGFR and HER3

Advanced Science, EarlyView.
By decreasing cholesterol and lipid raft levels in the plasma membrane, proprotein convertase subtilisin/kexin type 9 (PCSK9) boosts human epidermal growth factor receptor 1 and 3 (EGFR and HER3) activation, driving tumor growth and metastasis in triple‐negative breast cancer (TNBC).
Tianhong Li, Renfei Wu, Kathy Qian Luo
wiley   +1 more source

The development of a novel immunotherapy model of human ovarian cancer in human PBL-severe combined immunodeficient (SCID) mice

, 1995
William Walker, Grant Gallagher
openalex   +2 more sources